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Objective: The past decades have seen a surge in stimulant prescriptions for the treatment of attention-
deficit/hyperactivity disorder (ADHD). Stimulants acutely alleviate symptoms and cognitive deficits 
associated with ADHD by modulating striatal dopamine neurotransmission, and induce therapeutic 
changes in brain activation patterns. Long-term functional changes after treatment are unknown, as long-
term studies are scarce and have focused on brain structure. In this observational study (2009-2012), we 
investigated associations between lifetime stimulant treatment history and neural activity during reward 
processing.  
Method: Participants fulfilling DSM-5 criteria for ADHD (N=269) were classified according to stimulant 
treatment trajectory. Of those, 124 performed a monetary incentive delay task during magnetic resonance 
imaging, all in their non-medicated state (nearly&intense=51; nlate&moderate=49; nearly&moderate=9; nnaive=15; mean 
age=17.4 years, range 10-26 years). Whole-brain analyses were performed with additional focus on the 
striatum, concentrating on the two largest treatment groups.  
Results: Compared to the ‘late-and-moderate’ treatment group, the ‘early-and-intense’ treatment group 
showed more activation in the supplementary motor area and dorsal anterior cingulate cortex 
(SMA/dACC) during reward outcome (cluster size=8696 mm
3
; pCLUSTER<0.001). SMA/dACC activation 
of the control group fell in between the two treatment groups. Treatment history was not associated with 
striatal activation during reward processing. 
Conclusion: Our findings are compatible with previous reports of acute increases of SMA/dACC activity 
in individuals with ADHD after stimulant administration. Higher SMA/dACC activity may indicate that 
patients with a history of intensive stimulant treatment, but currently off-medication, recruit brain regions 















Stimulant treatment is the medical intervention of first choice for children and adolescents with 
attention-deficit/hyperactivity disorder (ADHD). The past decades have seen a surge in stimulant 
prescription rates.
1
 Alleviation of symptoms and cognitive deficits associated with ADHD appears – in 
general – not to last after medication is discontinued, and there is little evidence of long-term improved 
functioning.
2-4
 The absence of conclusive evidence regarding potential long-term effects of stimulant 
treatment, either positive or negative, has unsettled parents, patients, and society at large.  
Studies of long-term stimulant treatment effects on brain structure have yielded mixed results. 
Two meta-analyses found that striatal volume was more reduced in patients compared to controls when 
the ADHD sample included more treatment-naive patients,
5,6
 suggesting that striatal volume reduction 
observed in ADHD is driven by untreated rather than stimulant-treated patients. However, a large-scale 
longitudinal study, which employed the optimal design for the study of long-term treatment effects, did 
not find such treatment effects,
7
 nor did previous analyses in our own sample.
8,9
 
The literature on long-term treatment effects in the human brain has, with few exceptions, 
focused on brain structure, while studies of acute stimulant effects focused on brain activation patterns. A 
single dose of methylphenidate has repeatedly been found to alter brain activation patterns in ADHD 
patients; case-control differences in blood-oxygen level dependent (BOLD)-response to 
cognitive/motivational tasks became smaller or disappeared when patients were on stimulant 
medication.
10
 Little is known about whether acute functional changes translate into long-term functional 
changes as well. Adults with a history of untreated childhood ADHD showed blunted ventral-striatal 
activation compared to controls when exposed to emotional pictures, whereas adults with a history of 
ADHD who had received stimulant treatment during childhood did not.
11
 During reward processing, the 
same group of treatment-naive adults showed lower insula activation compared to controls and childhood 
stimulant-treated adults.
12
 These findings may suggest enduring functional therapeutic changes. In a meta-














 Radio-ligand studies, however, have reported exacerbated rather than attenuated deficits 
in striatal dopamine neurotransmission after long-term stimulant treatment in adults with ADHD.
14,15
 
Summarizing, stimulant treatment may be associated with persistent changes in brain activation patterns 
and/or dopamine metabolism, but the evidence is very limited and it remains unclear to what extent such 
changes may be therapeutic or disadvantageous.  
The striatum is of particular interest when studying stimulant treatment effects in ADHD. 
Reduced striatal volumes,
5,6
 lower striatal activity during reward anticipation and higher striatal activity 
during outcome of reward
16-18
 have repeatedly been found in ADHD. Moreover, the striatum is rich in 
dopamine transporters, an important molecular target of stimulant treatment. Hence, long-term stimulant 
treatment effects may be expected to occur in the striatum. However, acute stimulant-induced changes in 
activation patterns have also been reported in supplementary motor areas (SMA), frontal cortex, anterior 
and posterior cingulate cortex, and precuneus cortex.
e.g.,19-21
 
We investigated associations between lifetime stimulant treatment history and neural activity 
during reward processing, using magnetic resonance (MRI) data from a large observational study. An 
innovative data-driven classification method was used to identify patient subgroups with distinct 
treatment trajectories (e.g., early-onset-high-dose). In our cohort, A. Groenman, PhD, found these 
trajectories to be clinically relevant for the development of substance use disorder (unpublished data, 
2015). Moreover, treatment timing and dose have been found to moderate long-term stimulant treatment 
effects in the rat brain.
e.g.,22
 In prior work, our group showed higher striatal BOLD-response to reward 
outcome in ADHD patients compared to controls.
18
 In the current study, we hypothesized that patients 
who had received more intense treatment would show reduced striatal BOLD-response (i.e., more similar 
to controls) to reward outcome compared to those who had received less intense treatment. Second, we 

















Participants with ADHD were selected from the family-based IMAGE-NeuroIMAGE cohort 
(2009-2012).
23
 Children, adolescents, and young adults participated in diagnostic interviews, 
questionnaires, DNA collection, and an MRI session, taking  place at two sites. Informed consent was 
signed by all participants ≥12 years old and all parents of participants <18 years old. The study was 
approved by the local ethical committees of each participating site. Inclusion criteria were: IQ≥70, age 8-
30 years, no diagnosis of classical autism, learning difficulties, brain disorders, or genetic disorders, and 
no contra-indication for MRI scanning. ADHD diagnosis (any type) was confirmed in accordance with 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),
24
 operationalized as six or more 
symptoms on the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-
SADS
25
) and t>63 on the Conners parent-, teacher-, and/or self-rated ADHD scales,
26-28
 rated while 
participants were off-medication. Five K-SADS symptoms were sufficient for diagnosis in participants 
age 16 or older, in line with DSM-5 revised criteria. The initial ADHD sample consisted of 269 
participants. Functional MRI data were available for 124 patients (mean age=17.4 years, range 10-26 
years).  
Control participants were required to have no scores in the (sub)clinical range on any of the 
ADHD rating scales or interviews, no current or past psychiatric diagnosis or treatment, and no 
psychiatric diagnoses in first-degree relatives. The initial control sample consisted of 187 participants. 
Functional MRI data was available for 97 controls (mean age=17.0 years, range 10-23 years).  
 
Stimulant treatment  
 
History of psychoactive treatment was assessed using pharmacy prescription records containing 
delivery date, substance name, dose, quantity, and frequency of use for each delivery between date-of-
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interviews to reconstruct lifetime treatment history. Self-report data was highly compatible with data 
derived from pharmacies (data not shown), with reliability estimates similar as those reported by Kuriyan 
et al.
29
 Self-report data was used only when pharmacy data was incomplete. Stimulant intake in mg 
(immediate- and extended-release methylphenidate preparations, and dexamphetamine preparations) was 
reconstructed for each day between date-of-birth and date-of-scan. Daily intake in mg was averaged for 
every month of the participant’s life. Stimulant start age, stop age, and lifetime cumulative stimulant dose 
were calculated from this reconstruction. A smooth generalized additive model curve was fitted to each 
participant’s reconstruction, allowing estimation of three additional treatment parameters that were more 
sensitive to noise, i.e., treatment duration (estimated stop age minus estimated start age), treatment 
variability (standard deviation of the fitted curve), and the lifetime maximum dose. Treatment duration 
and cumulative stimulant dose were adjusted for current age. The use of non-stimulant psychoactive 
medication (e.g., risperidone, atomoxetine) was common, hence participants with a history of non-
stimulant psychoactive medication were not excluded. 
 
Community detection algorithm 
 
The six stimulant treatment parameters (start age, stop age, total dose, estimated duration, 
estimated maximum daily dose, and estimated variability) were entered in an automated, optimization-
based, weight-conserving community detection algorithm.
30
 This algorithm, implemented in R, is 
intuitively interpretable and less computationally expensive as compared to e.g. finite mixture models. It 
categorizes participants into mutually exclusive communities (groups), segregating groups such that 
within-group positive/negative correlations are maximal while between-group correlations are minimal. 
The modularity statistic Q (range 0-1) quantifies the degree to which participants may be subdivided into 
clearly delineated groups. The algorithm terminates when Q no longer increases from one iteration to the 
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The data-driven classification method produces more reliable results in larger samples, hence all 
participants with ADHD were included in this step (N=269). Stimulant-naive participants were a priori 
defined as a separate category (n=42, 15.1%). For stimulant-treated participants, the optimal solution 
yielded three treatment groups (Q=0.580; Table 1). The first group (n=111, 41.3%, ‘early-and-intense’) 
was characterized by early treatment onset, long duration, and a high maximum and total dose. The 
second group (n=96, 35.7%; ‘late-and-moderate’) was characterized by older age at treatment onset, 
shorter duration, and lower maximum and total dose. The third group (n=20, 7.4%; ‘early-and-moderate’) 
was characterized by early treatment onset, medium duration, and low maximum and total dose. As few 
participants were classified to the ‘early-and-moderate’ group or were stimulant-naive, ‘early-and-
intense’-vs.-‘late-and-moderate’ was our primary contrast of interest. As shown in Table 1, the ‘early-and-
intense’ and ‘late-and-moderate’ groups differed in stimulant start age, treatment duration, variability, 




A modified version of the monetary incentive delayed task was performed in the scanner.
18
 
Participants were asked to respond as quickly as possible to a target by pressing a button. Before this 
target, a cue indicated the possibility of gaining a reward after a button press within a given time-window. 
Every trial ended with a feedback screen informing about the outcome of the current trial. Depending on 
the participants’ performance, the response-window for a correct response was adapted in the next trial, 
resulting in an expected hit-rate of 33%. The experiment lasted 12 minutes, and a total of €5 could be 
gained. At the end of the experiment, the awarded money was paid to the participant. Compared with the 
original task, our version differed on two main aspects: hit-rate (33% versus 66%) and reward magnitude 
(€0.20 versus $5). The rationale behind these adaptations was firstly to increase the demands of the task 
with stronger task engagement as a result. Secondly, our adaptations aimed at meeting the practical 
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rewarding participants according to the original task parameters would have led to disproportionate 
monetary rewards (approximately €80), which was a concern for us and our ethical review board. 
Reaction time reward sensitivity was calculated as the mean reaction time across non-rewarded trials 
minus the mean reaction time across rewarded trials, with higher values indicating higher sensitivity to 
reward.  
 
Functional MRI processing and analyses 
 
 Acquisition parameters, preprocessing steps, and first-level analyses were identical to those in our 
previous publication
18
 (eAppendix2). Second-level analyses for each task condition (reward anticipation 
and outcome) comprised both region of interest (ROI) and whole-brain analyses in FMRIB Software 
Library (FSL).
31
 First, main task effects were identified in a one-sample t-test, with scanner, age, gender, 
and three motion parameters as regressors of no interest. For the ROI analyses, average parameter 
estimate was extracted for each participant from the (warped) task-activated voxels within a binary mask 
of the striatum (caudate, putamen, and accumbens). In a linear mixed effect regression model in SPSS,
32
 
striatal activation was predicted from treatment group (primary contrast: ‘early-and-intense’-vs.-‘late-and-
moderate’; secondary contrasts: ‘stimulant-naive’-vs.-‘early-and-intense’, ‘stimulant-naive’-vs.-‘late-and-
moderate’, ‘stimulant-naive’-vs.-‘early-and-moderate’, ‘early-and-moderate’-vs.-‘early-and-intense’, 
‘early-and-moderate’-vs.-‘late-and-moderate’). Gender, scanner, age, and age
2
 (to account for non-linear 
developmental trajectories of reward-related striatal activation
33
) were added as covariates, along with a 
random intercept per family to account for relatedness within the sample. Given our research question, 
alpha was adjusted for analyzing one primary and five secondary group contrasts in two task conditions 
(α=0.05/6/2=0.004). The same alpha was applied for all covariates included in the model (i.e., gender, 
age, scanner). Normalized first-level b-maps were entered into whole-brain second-level mixed effect 
analyses. Treatment group was entered as a predictor along with scanner, gender, age, and three 
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Structural MR images were also acquired, to assess structural correlates of long-term functional 
changes, if any (eAppendix3).  
 
Follow-up and sensitivity analyses 
 
For each whole-brain significant cluster, average parameter estimate was extracted per participant 
for follow-up analyses in SPSS. Treatment groups were data-driven, hence not matched with regard to 
clinical and demographic variables. Potential confounders other than age and gender (i.e., IQ, SES, 
ADHD symptoms, ADHD-type, comorbidity, and history of non-stimulant psychoactive medication) 
were added to the model. Moreover, analyses were repeated within one-to-one age-, gender-, and ADHD 
symptom count-matched subsamples (n=25 per group).  
To exclude acute withdrawal/rebound effects, each significant effect was re-estimated separately 
for participants who were on active stimulant treatment within two weeks prior to scanning and those who 
had ceased treatment more than two weeks prior to scanning.  
Main reward task effects and case-control differences in the current cohort have previously been 
reported,
18
 hence are not addressed here. For reference only, the control sample mean for each outcome 






The ADHD sample consisted of 83 males (66.9%) and 41 females (33.1%), with an average age 
of 17.4 years (SD=3.0, range 10-26 years; Table 2). Of those, 51 participants were assigned to the ‘early-
and-intense’ treatment group (46.8%), and 49 to the ‘late-and-moderate’ group (45.0%). Compared to the 
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participants on active stimulant treatment, and had more attention problems. The two groups did not differ 
with regard to age, socio-economic status, IQ, ADHD-type, hyperactivity/impulsivity symptoms, 
comorbidity, or history of non-stimulant medication. The control sample (n=97; mean age=17.0 years, 
SD=2.9, range 10-23 years) contained fewer males compared to the ADHD sample (44.3% vs. 66.9%; 




The striatum was activated by both task conditions (Figure 1). There were no differences in 
striatal BOLD-response between the ‘early-and-intense’ and ‘late-and-moderate’ treatment groups during 
reward anticipation (MeanEARLY&INTENSE=360.7, MeanLATE&MODERATE=394.8, MeanCONTROL=299.7, 
p=0.784), or during reward outcome (MeanEARLY&INTENSE=362.1, MeanLATE&MODERATE=677.5, 
MeanCONTROL=414.9; p=0.180).  
Whole-brain analyses did not yield any clusters of significant difference between the ‘early-and-
intense’ and the ‘late-and-moderate’ groups during reward anticipation. In the reward outcome condition, 
the ‘late-and-moderate’ group showed lower activity compared to the ‘early-and-intense’ group in a 
cluster located in the SMA, extending into the dorsal anterior cingulate cortex (dACC) and paracingulate 
gyrus (Figure 2; MeanEARLY&INTENSE=635.1, MeanLATE&MODERATE=-813.9, MeanCONTROL=35.5, cluster 
size=8696 mm
3
, B=-1449.0, pCLUSTER<0.001). Gender (B=964.6, p=0.014), scanner (B=179.0, p=0.604), 
age (B=-285.8, p=0.087), and age
2
 (B=153.8, p=0.087) were not associated with activation in this cluster, 
nor were any of the additional covariates (e.g., IQ, ADHD symptoms, non-stimulant treatment history, 
and comorbidity including substance use disorders) when added to the model while the effect of treatment 
history remained unchanged. Moreover, the pattern was consistently observed in past users 
(MeanEARLY&INTENSE=374.9, MeanLATE&MODERATE=-687.3) and current users (MeanEARLY&INTENSE=785.0, 
MeanLATE&MODERATE=-1323.6), and within the age-, gender-, and symptom-matched subsamples 
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There was no behavioral (i.e., reaction time) difference in reward sensitivity between the ‘early-
and-intense’ and ‘late-and-moderate’ groups (MeanEARLY&INTENSE=35.0ms, MeanLATE&MODERATE=29.4ms, 
p=0.559, for reference: MeanCONTROL=25.7ms). Moreover, reaction time reward sensitivity was not 
associated with striatal activity during reward anticipation (Pearson r=0.173, p=0.055) or reward outcome 
(Pearson r=0.014, p=0.879), nor with activity within the SMA/dACC cluster (Pearson r=0.177, p=0.050).  
There were no structural brain differences between the two groups. For findings involving the 




In a large sample of children, adolescents and young adults with ADHD, we investigated whether 
characteristics of stimulant treatment history were associated with brain activation patterns during reward 
processing while off medication. Stimulant treatment history was not associated with BOLD-response to 
reward anticipation or outcome in the striatum. In the SMA/dACC, individuals with a history of moderate 
treatment showed lower activity during reward outcome compared to those with a history of intense 
treatment. While activity in the moderately treated group was reduced compared to controls, activity in 
the intensely treated group was higher compared to controls. Our findings thus suggest compensatory 
SMA/dACC recruitment in individuals with a history of intense stimulant treatment. The effect is likely 
driven by treatment duration and dose rather than recency of treatment discontinuation, since stop age did 
not differ between the two groups. 
Higher striatal BOLD-response to reward outcome has consistently been reported in 
ADHD.
e.g.,17,18
 As such changes have been shown to disappear after stimulant administration,
16,34
 we had 
hypothesized that participants with a history of intense treatment would show lower striatal BOLD-
response to reward outcome compared to those with a history of less intense treatment. We found no 
evidence for such an effect. Moreover, there was no association between treatment history and striatal 
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response to stimulants do not translate into lasting functional changes in this region during reward 
processing. This finding is consistent with Stoy et al
12
 who, in a small adult sample, also reported no 
changes in striatal activation during reward outcome after childhood stimulant treatment.  
We found a large cluster of lower activity during reward outcome in the moderately treated 
subgroup compared to the intensely treated subgroup, located in the bilateral SMA and dACC, extending 
into the precuneus and posterior cingulate cortex. Dorsal and mid-cingulate regions project to the ventral 
striatum, and are important for monitoring incentive-based behavioral responses.
35,36
 Hypo-activation has 
previously been reported in medication-naive ADHD patients during reward outcome.
37
 Acute stimulant 
effects in the SMA/dACC during reward processing have been reported as well,
16
 although most fMRI 
studies of reward reported no acute stimulant effects in this region.
e.g.,21,34
  
Lower activity in the SMA/dACC in ADHD patients has also been associated with cognitive 
processes other than reward processing. Higher SMA/dACC activation may represent recruitment of a 
cognitive process enhancing feedback-based decision-making, even when a motor response is not 
required,
38,39
 as was the case in the reward outcome phase of our task. ADHD patients have shown lower 
SMA activity when selection of a non-habitual response was required.
13,40
 Higher SMA/dACC, PCC, and 
precuneus activity has been reported after a single dose of stimulants during tasks requiring feedback-
based modulation of motor responses,
41-43
 but acute effects in the opposite direction have also been 
reported.
10,44
 Enhanced cognitive decision-making upon reward in intensely-treated individuals is 
consistent with the lower rate of substance use disorder in this group (A. Groenman, PhD, unpublished 
data, 2015), although the difference in substance use disorder rate in the current (smaller) fMRI sample 
was not significant. Summarizing, higher SMA/dACC activity may indicate enhanced cognitive decision-
making following reward after early and high-dose stimulant treatment. Note that this proposition is not 
supported in behavioral data, as our paradigm required no response following reward outcome. 
Alternatively, higher SMA/dACC activity may represent increased salience network activity, 
enhancing attention allocation to emotional, rewarding, or surprising events.
45
 Stimulant-induced 
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Stimulant treatment history may be associated with greater task focus. Yet, increased task focus may be 
expected to occur throughout the task as opposed to during the outcome phase only, and may result in 
improved task performance which we did not observe. Finally, higher SMA/dACC activity may entail 
enhanced ‘readiness to act’ upon reward outcome, as the SMA is embedded in the task-positive motor 
network.
48
 However, we found no association between SMA/dACC activation and reaction times.  
The current study has several strengths. First, only a handful of prior studies investigated 
functional rather than anatomical long-term neural changes in relation to stimulant treatment in ADHD. 
Of those, the current sample is by far the largest. Second, the data-driven classification of participants 
with ADHD based on multiple treatment characteristics is novel and clinically relevant. The current study 
has limitations as well. Long-term treatment effects can only be studied observationally. Although 
findings have been statistically adjusted for group differences, confounding by indication could not be 
excluded. Moreover, few participants were stimulant-naïve (in accordance with high prescription rates), 
and data-driven classification of stimulant-treated participants yielded unbalanced groups. This allowed 
powerful analysis of participants in the two largest groups, but restricted analyses of stimulant-naive 
participants and those with early-and-moderate treatment. Finally, no data was collected regarding 
behavioral treatment which, according to guidelines, should be offered in conjunction with 
pharmacological treatment; hence, pharmacological and behavioral treatment effects cannot be 
distinguished in our study. The recruitment of compensatory cognitive control areas may reflect the 
application of cognitive strategies learned during behavioral treatment.   
We conclude that ADHD patients with a history of early-onset high-dose stimulant treatment 
showed more SMA/dACC activation during reward outcome, compared to those with a history of late-
onset moderate-dose stimulant treatment. Higher SMA/dACC activity may represent a compensatory 
mechanism of enhanced higher-level processing of reward information in the intensely treated group. 
Stimulant treatment history was not associated with striatal BOLD-response to reward processing. 
Understanding long-term risk and benefits of stimulant treatment could be further enhanced by evaluating 















- Stimulant treatment is regarded a safe and effective treatment for ADHD symptoms, yet their 
long-term effects on brain activation patterns in children and adolescents are largely unknown.  
- Early and intense stimulant treatment may result in increased activation of cognitive control areas 
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